Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 14 studies | 20% ± 4% | |
| oligodendrocyte | 12 studies | 30% ± 10% | |
| endothelial cell | 9 studies | 28% ± 12% | |
| microglial cell | 9 studies | 27% ± 9% | |
| oligodendrocyte precursor cell | 9 studies | 29% ± 12% | |
| astrocyte | 9 studies | 27% ± 10% | |
| endothelial cell of lymphatic vessel | 8 studies | 25% ± 9% | |
| GABAergic neuron | 7 studies | 39% ± 20% | |
| glutamatergic neuron | 6 studies | 46% ± 23% | |
| interneuron | 5 studies | 39% ± 20% | |
| Mueller cell | 4 studies | 20% ± 2% | |
| granule cell | 3 studies | 31% ± 14% | |
| adventitial cell | 3 studies | 17% ± 1% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 9 studies | 37% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 1346.89 | 244 / 245 | 99% | 7.78 | 498 / 502 |
| thymus | 100% | 1772.69 | 651 / 653 | 98% | 6.71 | 591 / 605 |
| breast | 100% | 2915.78 | 459 / 459 | 95% | 10.60 | 1062 / 1118 |
| adrenal gland | 99% | 1040.51 | 255 / 258 | 96% | 13.07 | 220 / 230 |
| brain | 91% | 715.85 | 2406 / 2642 | 100% | 7.66 | 704 / 705 |
| lung | 100% | 3012.99 | 577 / 578 | 90% | 6.00 | 1039 / 1155 |
| skin | 96% | 4925.34 | 1734 / 1809 | 93% | 8.54 | 437 / 472 |
| kidney | 90% | 733.28 | 80 / 89 | 96% | 9.07 | 861 / 901 |
| ovary | 100% | 2101.56 | 180 / 180 | 83% | 3.96 | 356 / 430 |
| intestine | 98% | 1499.37 | 943 / 966 | 70% | 3.70 | 370 / 527 |
| esophagus | 92% | 1728.63 | 1325 / 1445 | 73% | 4.16 | 134 / 183 |
| bladder | 100% | 2006.52 | 21 / 21 | 63% | 3.31 | 317 / 504 |
| stomach | 87% | 1212.21 | 314 / 359 | 75% | 4.80 | 214 / 286 |
| uterus | 100% | 2773.32 | 170 / 170 | 59% | 4.65 | 273 / 459 |
| pancreas | 25% | 128.77 | 82 / 328 | 93% | 8.58 | 166 / 178 |
| adipose | 100% | 2738.86 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 3005.69 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 100% | 931.81 | 240 / 241 | 0% | 0 | 0 / 0 |
| heart | 94% | 971.16 | 806 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 4.41 | 26 / 29 |
| liver | 24% | 128.48 | 54 / 226 | 57% | 2.75 | 230 / 406 |
| eye | 0% | 0 | 0 / 0 | 66% | 2.74 | 53 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 53% | 1.97 | 24 / 45 |
| muscle | 38% | 218.67 | 307 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 10% | 49.45 | 94 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0001955 | Biological process | blood vessel maturation |
| GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
| GO_1904684 | Biological process | negative regulation of metalloendopeptidase activity |
| GO_0030198 | Biological process | extracellular matrix organization |
| GO_0090210 | Biological process | regulation of establishment of blood-brain barrier |
| GO_0035115 | Biological process | embryonic forelimb morphogenesis |
| GO_0060070 | Biological process | canonical Wnt signaling pathway |
| GO_0045765 | Biological process | regulation of angiogenesis |
| GO_0002040 | Biological process | sprouting angiogenesis |
| GO_1903053 | Biological process | regulation of extracellular matrix organization |
| GO_0030336 | Biological process | negative regulation of cell migration |
| GO_0007566 | Biological process | embryo implantation |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016020 | Cellular component | membrane |
| GO_1990909 | Cellular component | Wnt signalosome |
| GO_0098552 | Cellular component | side of membrane |
| GO_0017147 | Molecular function | Wnt-protein binding |
| GO_0015026 | Molecular function | coreceptor activity |
| GO_0004866 | Molecular function | endopeptidase inhibitor activity |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0008191 | Molecular function | metalloendopeptidase inhibitor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | RECK |
| Protein name | Reversion-inducing cysteine-rich protein with Kazal motifs (hRECK) (Suppressor of tumorigenicity 15 protein) RECK protein |
| Synonyms | ST15 |
| Description | FUNCTION: Functions together with ADGRA2 to enable brain endothelial cells to selectively respond to Wnt7 signals (WNT7A or WNT7B) . Plays a key role in Wnt7-specific responses: required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation (By similarity). Acts as a Wnt7-specific coactivator of canonical Wnt signaling by decoding Wnt ligands: acts by interacting specifically with the disordered linker region of Wnt7, thereby conferring ligand selectivity for Wnt7 . ADGRA2 is then required to deliver RECK-bound Wnt7 to frizzled by assembling a higher-order RECK-ADGRA2-Fzd-LRP5-LRP6 complex . Also acts as a serine protease inhibitor: negatively regulates matrix metalloproteinase-9 (MMP9) by suppressing MMP9 secretion and by direct inhibition of its enzymatic activity . Also inhibits metalloproteinase activity of MMP2 and MMP14 (MT1-MMP) . . |
| Accessions | O95980 Q6P9E2 ENST00000377966.4 |